CurrentWellCarePolicy MC.CP.MP.248

Facility-based Sleep Studies for Obstructive Sleep Apnea

Customize your policy alerts

Sign up for WellCare Policy MC.CP.MP.248 alerts

Get alerted when Policy MC.CP.MP.248 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical necessity criteria and coding guidance for facility-based polysomnography (PSG), split-night studies, and CPAP/BiPAP titration for adults with suspected obstructive sleep apnea; applies to WellCare/Centene-affiliated health plans.

Policy Summary

PayerWellCare

PolicyFacility-based Sleep Studies for Obstructive Sleep Apnea

Policy CodePolicy MC.CP.MP.248

Change TypeNo material change noted

Effective Date

Next Review Date

Key ActionDocument suspected OSA and why home sleep apnea testing (HSAT) is inappropriate when requesting facility-based PSG.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥18age for covered facility-based PSG

BMI ≥50high-risk BMI listed

95807–95811supported CPTs

95803not supported CPT

33+

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentWellCarePolicy MC.CP.MP.248

Facility-based Sleep Studies for Obstructive Sleep Apnea

Customize your policy alerts

Sign up for WellCare Policy MC.CP.MP.248 alerts

Get alerted when Policy MC.CP.MP.248 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerWellCare

PolicyFacility-based Sleep Studies for Obstructive Sleep Apnea

Policy CodePolicy MC.CP.MP.248

Change TypeNo material change noted

Effective Date

Next Review Date

Key ActionDocument suspected OSA and why home sleep apnea testing (HSAT) is inappropriate when requesting facility-based PSG.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥18age for covered facility-based PSG

BMI ≥50high-risk BMI listed

95807–95811supported CPTs

95803not supported CPT

33+

Coverage Criteria for Facility-Based PSG and Related Testing

Initial facility-based PSG

Covered when ALL of the following are met:

Initial PSG criteria: Member/enrollee has suspected obstructive sleep apneaage >=18

HSAT not appropriate

Reasons HSAT not appropriate: 1. Portable/HSAT services are not available; 2. Member is unable to properly operate or tolerate home study equipment and another individual is not available to assist; 3. Previous HSAT results are negative or inadequate for diagnosis and/or autotitration of APAP for suspected OSA; 4. Chronic opioid use; 5. Low pretest probability of OSA (normal BMI <30, Mallampati score 1–2, no snoring, normal neck circumference); 6. Member works in a mission-critical function (e.g., pilots, commercial drivers, public safety personnel) where falling asleep at work would have major negative impact; 7. BMI ≥ 50 kg/m2; 8. Presence of specified risk factors and signs/symptoms (e.g., moderate to severe chronic pulmonary disease, refractory hypertension on three or more antihypertensives including a diuretic with uncontrolled BP, observed apnea or choking episodes).

Combined requirement: All of the above criteria must be documented in the medical record to support medical necessity for an initial facility-based PSG or split-night study.

Repeat facility-based PSG

Covered when ALL of the following are met:

Repeat PSG prerequisites: All of the criteria in the Initial PSG section (Section I.B) are met

Study frequency threshold: The requested study and any previous studies amount to two or less per rolling year<=2 studies per rolling year

Clinical reasons for repeat PSG (one or more required): 1. Oral appliance adjusted for fit and requires assessment of efficacy; 2. Change of device needed due to intolerance of current device; 3. Assessment of whether PAP settings need change (including continued symptoms despite adherent use: ≥4 hours/night for 70% of nights over a 30‑day period); 4. Significant weight loss (>10%) while on PAP to determine if PAP can be discontinued; 5. Significant weight gain or recurrent symptoms where repeat study would inform PAP reinstitution; 6. Postoperative assessment of efficacy after upper airway surgery for OSA; 7. Remote history of OSA and not on PAP with need to re-establish diagnosis/initiate CPAP; 8. New signs or symptoms after prior negative study (e.g., weight gain with symptoms, new nocturia); 9. Initial polysomnogram negative but clinical suspicion for OSA remains and a second polysomnogram is considered.

CPAP/BiPAP titration

Covered when ONE of the following is met:

Titration: A. Member meets criteria in section I for facility-based sleep study and has not attempted a home-based APAP titration; OR B. Diagnosed with OSA during HSAT and there is evidence/documentation of failure of an APAP trial (e.g., downloaded compliance data).

Actigraphy

Actigraphy stance: Insufficient evidence to support the use of actigraphy testing alone for diagnosis of obstructive sleep apnea; CPT 95803 is not supported for coverage.

The policy states that there is insufficient evidence to support the use of actigraphy testing alone for diagnosis of obstructive sleep apnea. Actigraphy (CPT 95803) is explicitly listed among the CPT codes that do not support coverage, and the policy indicates its effectiveness for OSA diagnosis has not been established. Providers should not substitute actigraphy for facility-based polysomnography (PSG) when seeking coverage for diagnostic evaluation of suspected OSA.

When state Medicaid coverage provisions conflict with this clinical policy, the state Medicaid rules take precedence. Coverage decisions and administration of benefits remain subject to the terms, exclusions, and limitations in plan coverage documents and to applicable state and federal requirements; providers should follow applicable Medicaid policy where it differs from this guideline.

Home sleep apnea testing (HSAT) is presented as a preferred initial diagnostic option for many adults at high pretest probability for moderate-to-severe OSA because HSAT demonstrates high sensitivity and specificity in selected populations and offers convenience and cost advantages. For most patients with suspected mild OSA, however, the policy notes that facility-based PSG is preferred because HSAT measures fewer physiologic variables and may under-detect sleep-related events. Facility-based PSG or attended titration may therefore be unnecessary when HSAT is appropriate, available, and yields adequate diagnostic information; conversely, facility-based PSG is indicated when HSAT is unavailable, inappropriate, inadequate, or has failed.

Coding Guidance and Diagnostic Thresholds

CPT codes that support coverageCPTCovered

95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist.
95808	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist.
95810	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.
95811	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist.

CPT codes that do not support coverageCPTNot Covered

95803

Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording).

inv-10: OSA diagnostic event thresholds — diagnostic AHI criteria

Diagnostic AHI threshold (symptomatic)≥ 5 predominantly obstructive respiratory events per hour in the presence of symptoms or certain comorbidities

Diagnostic AHI threshold (asymptomatic)≥ 15 predominantly obstructive respiratory events per hour in asymptomatic patients

Source classificationThresholds per the International Classification of Sleep Disorders as cited in policy background

Prior Authorization, Documentation, and Provider Responsibilities

Prior Authorization

Prior authorization required: facility-based PSG (initial, repeat, titration)

Initial, repeat, and CPAP/BiPAP titration facility-based polysomnography (PSG) procedures (CPT 95807, 95808, 95810, 95811) are medically necessary only when the policy's clinical criteria are documented and met (e.g., suspected OSA and one or more reasons HSAT is not appropriate or listed repeat/titration indications). Providers must demonstrate the applicable clinical criteria when requesting authorization for these facility-based PSG services.

Codes referenced: 95807, 95808, 95810, 95811.
Initial PSG requires suspected OSA and HSAT not appropriate for one or more listed reasons (see policy).
Repeat PSG limited to ≤2 studies per rolling year and requires meeting initial criteria plus specified clinical reasons.
Titration covered when initial PSG criteria met and no home-based APAP titration attempted, or when HSAT-diagnosed OSA has documented APAP trial failure.

Prior Authorization

Adhere to plan-level prior authorization and benefit terms

Background on Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is the most common form of sleep-disordered breathing characterized by partial or complete upper airway collapse during sleep, producing symptoms such as excessive daytime sleepiness and loud snoring. Polysomnography (PSG) remains the diagnostic gold standard because it records multiple physiologic parameters during sleep, whereas HSAT measures fewer variables and may miss events in certain patients; accordingly, facility-based PSG is generally favored when there is suspected mild OSA or when HSAT is not appropriate.

Definitions and Guideline References

inv-20: Polysomnography (PSG) — definition and monitored parameters

DefinitionContinuous and concurrent monitoring and recording of physiological parameters of sleep with physician evaluation and interpretation (Polysomnography, PSG)

Monitored parametersSleep staging, respiratory flow, respiratory effort, pulse oximetry/oxygen saturation, ventilation

PurposeDiagnose sleep disorders including OSA and evaluate response to treatments such as CPAP

inv-21: Obstructive sleep apnea (OSA) — definition and diagnostic thresholds summary

Core definition of OSASleep apnea characterized by partial or complete collapse of the upper airway during sleep leading to repetitive obstructive respiratory events

Diagnostic criteria (with symptoms/comorbidities)

Policy Summary

PayerWellCare

PolicyFacility-based Sleep Studies for Obstructive Sleep Apnea

Policy CodePolicy MC.CP.MP.248

Change TypeNo material change noted

Effective Date

Next Review Date

Key ActionDocument suspected OSA and why home sleep apnea testing (HSAT) is inappropriate when requesting facility-based PSG.

SourceLink

On This Page

Follow the Health Plan's administrative policies, benefit terms, and any plan-level authorization requirements and effective dates when seeking coverage for sleep studies; plan documents govern coverage determinations and prior authorization processes.

Check applicable plan-level authorization requirements and effective dates before submitting requests.
Coverage decisions are subject to the plan's terms, conditions, exclusions, and limitations.

Step Therapy

Use HSAT as preferred initial test when appropriate; reserve facility PSG when HSAT is unsuitable

When appropriate, home sleep apnea testing (HSAT) is the preferred initial diagnostic option for selected adults with high pretest probability of uncomplicated moderate-to-severe OSA; facility-based PSG should be requested only when HSAT is unavailable, inappropriate, inadequate, or fails.

HSAT advantages include convenience and cost effectiveness; facility PSG preferred for suspected mild OSA or when HSAT sensitivity is a concern.
Facility PSG is appropriate if HSAT services are not available, the member cannot operate HSAT, prior HSAT was inadequate/negative, chronic opioid use, mission-critical worker status, BMI ≥50 kg/m2, or listed comorbid risk factors.

Note

Provider responsibility: cite policy criteria and plan effective dates in authorization requests

Ensure prior authorization reflects clinical justification for facility-based testing and that requests reference relevant policy criteria and provider responsibility; confirm plan effective dates and any additional administrative requirements when submitting.

Include explicit linkage to the policy's clinical criteria when requesting facility-based PSG.
Confirm the Health Plan’s effective date for the clinical policy and adhere to any provider notification requirements.

Documentation Required

Required documentation: suspected OSA and why HSAT is not appropriate

Provide clinical documentation of suspected obstructive sleep apnea and a specific rationale why HSAT is not appropriate for this patient (select from the policy’s enumerated reasons) when requesting facility-based PSG.

Permissible reasons include: HSAT not available; inability to operate/tolerate HSAT without assistance; prior HSAT negative or inadequate; chronic opioid use; low pretest probability considerations; mission-critical worker status; BMI ≥50 kg/m2; or presence of listed comorbid risk factors with signs/symptoms.
Document prior HSAT attempts, downloaded APAP compliance data if relevant, and other supporting clinical details.

Note

Policy effective date — verify Health Plan–determined date and provider responsibilities

This clinical policy is effective as of the date determined by the Health Plan; providers must verify the Health Plan’s effective date and comply with any applicable legal or regulatory notification requirements when applying the policy.

The date of posting may not be the effective date—confirm the Health Plan–determined effective date before applying policy rules.
Providers are responsible for following any plan-level changes, amendments, or withdrawals to the clinical policy.

Denial Risk

Unsupported coding: actigraphy (CPT 95803) not supported

Actigraphy testing (CPT 95803) is not supported as a standalone diagnostic test for OSA and is considered unsupported by this policy; submissions using CPT 95803 in lieu of supported PSG/HSAT are likely to be denied.

Policy states insufficient evidence to support actigraphy testing alone for diagnosis of OSA.
Do not substitute CPT 95803 for facility-based PSG or appropriate HSAT methods when requesting coverage.

Denial Risk

Denial risk: coverage subject to plan documents, state Medicaid precedence, and legal requirements

Coverage decisions and benefit administration are subject to the Health Plan’s coverage documents, state Medicaid provisions, federal requirements, and plan-level administrative policies; conflicts with state Medicaid provisions are governed by those state rules and may override this clinical policy.

Verify member eligibility and applicable state Medicaid rules—state Medicaid provisions take precedence where they conflict with this clinical policy.
Coverage is not guaranteed by meeting medical necessity criteria alone; follow contract terms and plan exclusions/limitations.

≥ 5 predominantly obstructive respiratory events per hour

Diagnostic criteria (asymptomatic)≥ 15 predominantly obstructive respiratory events per hour

inv-22: OSA testing guidelines — cited clinical practice guidelines and literature

Primary guideline citedAmerican Academy of Sleep Medicine: Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea (Kapur et al., J Clin Sleep Med. 2017)

Titration guidanceClinical guidelines for manual titration of positive airway pressure (Kushida et al., J Clin Sleep Med. 2008)

Portable monitoring guidanceAASM Portable Monitoring Task Force guideline for unattended portable monitors (Collop et al., J Clin Sleep Med. 2007)